Vinay Prasad, the Food and Drug Administration's chief medical and science officer, resigned. He cited a desire to return to California and spend more time with his family. His departure followed controversial FDA decisions regarding Sarepta Therapeutics' gene therapy drug, Elevidys. The FDA had temporarily halted shipments after recipient deaths but later rescinded the suspension.